Acceleron readout supports sotatercept as disease-modifying option for PAH

Acceleron is readying to send its pulmonary arterial hypertension candidate to Phase III after announcing late Monday that the therapy combined with standard of care met primary and secondary endpoints in a proof-of-concept Phase II study.

Acceleron Pharma Inc. (NASDAQ:XLRN) gained $34.14 (65%) to $87.01 in after-hours trading following its report of top-line results for sotatercept in the Phase II PULSAR trial. If the move holds, it would represent a nearly $2 billion gain in market cap...